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Abstract
Introduction—Breast cancer in women aged 18–44 years accounts for approximately 27,000 
newly diagnosed cases and 3,000 deaths annually. When tumors are diagnosed, they are usually 
aggressive, resulting in expensive treatment costs. The purpose of this study is to estimate the 
prevalent medical costs attributable to breast cancer treatment among privately insured younger 
women.
Methods—Data from the 2006 MarketScan® database representing claims for privately insured 
younger women were used. Costs for younger breast cancer patients were compared with a 
matched sample of younger women without breast cancer, overall and for an active treatment 
subsample. Analyses were conducted in 2013 with medical care costs expressed in 2012 U.S. 
dollars.
Results—Younger women with breast cancer incurred an estimated $19,435 (SE=$415) in 
additional direct medical care costs per person per year compared with younger women without 
breast cancer. Outpatient expenditures comprised 94% of the total estimated costs ($18,344 [SE=
$396]). Inpatient costs were $43 (SE=$10) higher and prescription drug costs were $1,048 (SE=
$64) higher for younger women with breast cancer than in younger women without breast cancer. 
For women in active treatment, the burden was more than twice as high ($52,542 [SE=$977]).
Conclusions—These estimates suggest that breast cancer is a costly illness to treat among 
younger, privately insured women. This underscores the potential financial vulnerability of women 
in this age group and the importance of health insurance during this time in life.
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Introduction
Approximately 27,000 newly diagnosed breast cancer cases and 3,000 deaths occur annually 
in women younger than age 45 years.1 Breast cancer and its subsequent treatment pose 
several distinct challenges for women aged between 18 and 44 years (hereinafter referred to 
as younger women).2 When breast cancer presents in this age group, the tumors are often 
large and aggressive, requiring expensive treatment, conferring worse prognosis than in 
older women.3 Breast cancer tumors that are “triple negative” (negative for the estrogen, 
progesterone, and HER-2/neu receptors) are both more costly to treat4 and more prevalent in 
younger women than in older women.3,5,6
Breast cancer treatment may also be associated with a variety of side effects, including 
changes in reproductive health, treatment-induced early menopause, and changes to sexual 
function, which may be distinct from the concerns of an older population.3,7,8 The risk of 
early menopause may be as high as 35% for younger women undergoing chemotherapy.9 
Approximately 30% of women aged 40 years and younger have reported that fertility 
concerns played a role in their breast cancer treatment decisions and recent evidence has 
suggested that 10% of women may choose to undergo fertility preservation.10 Furthermore, 
privately insured women aged 65 and younger may incur substantial and expensive 
chemotherapy-related side effects.11
In addition, younger women with breast cancer are more likely to exhibit symptoms of 
depression than older breast cancer patients,12 more prone to emotional distress and anxiety,
13
 and are more likely to utilize mental health services.14 Previous research has shown that 
the odds of mental health care use among younger women diagnosed with breast cancer are 
more than six times higher than the odds among those aged ≥65 years.15
Taken together, these factors—aggressive cancer, adverse health effects of treatment, and 
increased utilization of mental healthcare services—suggest that breast cancer in younger 
women may result in a substantial financial burden for patients and their families. This study 
estimated the annual direct medical care costs attributable to breast cancer among privately 
insured younger women. The direct medical costs express the total amount of medical 
spending ascribed to breast cancer among younger women. Prevalent cost estimates are 
presented, reflecting costs in a single year among younger women with breast cancer across 
the entire treatment spectrum. Prevalence costs can be useful for informing the design of 
insurance benefits, eligibility criteria for public programs, and budgeting for future costs.16 
This paper reports the costs by type of service and also identifies women in active treatment 
during the year. Although many studies have focused on the Medicare population17 and on 
the privately insured population aged 65 years and younger,11,18 to the authors’ knowledge, 
no studies have previously examined breast cancer treatment costs in this younger 
population.
Methods
In this study, data from the MarketScan® database representing claims in 2006 (January 1 to 
December 31, 2006) were used, and the analyses were conducted in 2013.19 These data 
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represented the most recent version available to the authors at the initiation of this study. 
Marketscan’s Commercial Claims Database is one of the nation’s largest administrative 
claims database of privately insured individuals. The database included de-identified, 
person-specific outpatient, inpatient, and retail pharmaceutical claims from approximately 
100 large payers, representing millions of covered lives. The claims included visit-level 
information, including dates of service, diagnosis and procedure codes, and payments. The 
enrollment files contained the universe of individuals enrolled in health insurance plans at 
any time during the study period, even those without a claim, which allowed assessment of 
the duration of enrollment. No restrictions were made on the basis of enrollment. Further, 
the database contains demographic information of the enrollees, including age, gender, 
employment, and the first three digits of their ZIP code. The three-digit ZIP code was used 
to provide state identifiers for all 50 states and the District of Columbia.
ICD-9-CM codes were used to identify women with breast cancer. Women with breast 
cancer were those with
1. a malignant neoplasm of the female breast (174);
2. carcinoma in situ of breast (233.0);
3. a history of malignant conditions classifiable to the breast (V10.3); or
4. prescription for aromatase inhibitors.20,21
Beneficiaries with any inpatient or long-term care claims with any of these ICD-9-CM codes 
were identified as breast cancer patients. Beneficiaries were also identified as having breast 
cancer if there were at least two outpatient claims with these ICD-9-CM codes on different 
days, which excluded screening codes for breast cancer. The aromatase inhibitors 
exemestane (Aromasin); anastrozole (Arimidex); and letrozole (Femara) were identified in 
the prescription drug file by their National Drug Code.
In subsample analyses, the authors identified younger women with breast cancer in the 
active treatment phase of care by utilizing the ICD-9-CM diagnosis codes, ICD-9-CM 
procedure codes, Healthcare Common Procedure Coding System codes, and Diagnosis-
Related Group codes used in Appendix A of Hassett et al.11 for chemotherapy and radiation. 
Because most breast cancer patients receive either chemotherapy or radiation,22 women 
were considered in active treatment if they had a code for either.
The payment variables included all payments to providers associated with the administration 
of care, including out-of-pocket payments. Approximately one quarter of the MarketScan 
population was enrolled for less than a full year. As a result, payments were annualized by 
dividing by the fraction of the enrollment year. All costs were adjusted to 2012 U.S. dollars 
using a gross domestic product deflator.23
All comorbidities were defined using ICD-9-CM codes for claims at any point during 2006. 
This study included a modified Charlson Comorbidity Index that excluded diagnosis codes 
for cancers: any malignancy, leukemia and lymphoma, and metastatic solid tumors.24 
However, it controlled separately for the following cancers using indicator variables: 
ovarian, colorectal, lung, cervical, melanoma, leukemia, and lymphoma. Because the 
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Charlson Comorbidity Index includes many comorbidities that are most relevant to an older 
population, 12 additional conditions that were either prevalent or expected to be high cost 
among younger women (e.g., pregnancy, injuries, hypertension) were included as covariates 
in the multivariable models for this study.
Statistical Analysis
The authors propensity score matched younger women with breast cancer from the database 
to younger women without breast cancer. The propensity score estimates the probability of 
being in the breast cancer group based on the patient characteristics using predicted 
probabilities via a probit regression. The predicted values from the probit regression 
summarize multiple patient characteristics into a single propensity score, with similar scores 
indicating overlap in patient characteristics.25 The probit model included age, employment, 
state, the Charlson Comorbidity Index exclusive of cancer, indicators for the six other types 
of cancer, and the 12 additional comorbidities relevant to this population of younger women. 
Nearest neighbor matching was used to pair a breast cancer patient with a non–breast cancer 
comparison woman. Because covariate balance may not hold for subsets of the matched 
sample, the authors rematched using nearest neighbor matching for both the active treatment 
groups.26
As is often the case with medical expenditure data, the samples included some individuals 
with extremely high expenditures (1% of patients have costs more than ten times the sample 
mean).27 Less than 0.1% of breast cancer patients had zero expenditures, raising 
identification concerns with two-part model approaches for all expenditure categories. 
Almost all breast cancer patients had no inpatient expenditures (98%), and 16% had no drug 
expenditures.
These features of the data suggested that ordinary least squares estimates may be biased. To 
account for the bias, annual expenditures were predicted using two nonlinear model 
specifications. First, because so few patients lacked expenditures, total and outpatient 
expenditures were predicted using a generalized linear model for all patients to account for 
skewness. Second, the inpatient and drug expenditures were predicted with a two-part model 
to adjust for the substantial number of zero inpatient and drug expenditure.28 The first part 
of the two-part model was a logistic regression to predict the probability of any medical 
expenditure. The second part was a generalized linear model composed of individuals with 
positive expenditures. Tests of the data indicated that using a gamma distribution with a log 
link in the generalized linear model was appropriate in all specifications.28 Marginal effects 
of breast cancer were calculated using recycled predictions, and the delta method was used 
to compute SEs. All analyses were conducted in Stata, version 12.1.
Results
This study found 9,912 younger women with breast cancer and > 3.5 million without breast 
cancer. Table 1 presents the summary statistics for the breast cancer sample, all potential 
comparisons, and the matched comparison sample. The breast cancer group was older than 
the non-matched comparison group; almost 74% of the breast cancer group was aged 39–44 
years compared with only 29% of the non-matched comparison group. Breast cancer 
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patients had higher rates of comorbid conditions, incurred much higher medical care costs, 
and were diagnosed with more chronic disorders such as hypertension and dyslipidemia than 
patients without breast cancer. Younger women with breast cancer were significantly more 
likely to exhibit depression (5.9% vs 3.9%) and have mental health or substance abuse issues 
(13.1% vs 9.8%).
After matching, the two samples balanced on all covariates. The unadjusted differences in 
total annual medical care costs per woman were more than five times larger ($27,833 vs 
$4,831) for a younger woman with breast cancer than for a matched woman without breast 
cancer (Table 1). Inpatient costs were <$100 for each group.
Table 2 presents the results for the active and not active treatment subsamples. Of the 9,912 
breast cancer women, 3,065 (31%) were on active treatment. The mean total costs for the 
active treatment subsample were $68,096, more than ten times larger than the costs for the 
matched comparison sample and six times larger than breast cancer patients not on active 
treatment ($10,026). All covariates, including state indicators (not shown), balanced at the 
95% level.
Estimates from nonlinear specifications, broken down by type of service, are displayed in 
Table 3. Total costs attributable to breast cancer for the average privately insured younger 
woman were $19,435 (SE=$415). Outpatient expenditure was the largest component of 
medical spending attributable to breast cancer, estimated at $18,344 (SE=$396), comprising 
94% of total costs. Relative to outpatient costs, inpatient and prescription drug costs were 
much smaller at $43 (SE=$10) and $1,048 (SE=$64), respectively.
Women in active treatment incurred $52,542 (SE=$977) in additional medical expenditures 
per person, of which $50,291 (SE=$932) represented outpatient costs. Drug costs for women 
in active treatment were also more than twice the matched comparison sample ($2,170 [SE=
$185]).
Discussion
In this study, the annual excess direct medical care costs for breast cancer among privately 
insured younger women was estimated to be $19,435 per woman per year. Women in active 
treatment had a much larger burden, $52,542. These findings demonstrate the substantial 
economic burden among privately insured women aged 18–44 years with breast cancer.
Similar to previous studies,29 outpatient costs were the largest component of costs, 
comprising 94% of the total costs. Meanwhile, inpatient costs were the smallest component, 
comprising less than 1% of the total costs. Many breast cancer treatments occur in an 
outpatient setting such as hormonal therapies, lumpectomy, radiation therapy, and 
neoadjuvant and adjuvant chemotherapies.18
The direct medical care cost estimates reported here represent only a portion of the total 
financial burden of breast cancer in this population. The cost estimates presented in this 
study do not take into account all the economic cost that younger women incurred to receive 
medical care. These activities may include lost earning potential, time spent traveling to and 
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from care, waiting for appointments, consulting with physicians and other providers, child 
and dependent care costs, and leisure time. The activities forgone or incurred in receipt of 
medical care have been recommended for inclusion in economic studies of health 
interventions.30 Excluding these activities may result in an understimate of the economic 
burden associted with breast cancer treatment among younger women.
The magnitude of the overall estimates is smaller than the $42,401 per person annual 
treatment cost estimate reported by Fu and Jhaveri18 among a sample of privately insured 
women aged 18–64 years. There are a number of possible explanations for the differences in 
the estimates. Fu and Jhaveri focused on first-year costs only, which may be closer to the 
present estimate of those women in active treatment. The prevalence cost estimates reflect a 
cross section of annual attributable costs among women receiving breast cancer–related 
treatment at all phases of care across the cancer survivorship spectrum, from diagnosis 
through post-treatment care. Among cancer patients, previous studies have shown that 
expenditures are highest in the first year following diagnosis and at the end of life, and 
lowest in the intermediate phase.31
Limitations
This study has some limitations. First, although the sample is quite large, it represents a 
small portion of patients with commercial health insurance. However, the prevalence of 
breast cancer among the study population generally reflects the U.S. prevalence of breast 
cancer for this age group (results available on request).32 Second, the study lacked some 
sociodemographic characteristics (e.g., race and income) and information on cancer stage at 
diagnosis. Lack of this information limited the authors’ ability to report costs by subgroups 
and stage at diagnosis. Third, complications of treatment, such as mental health conditions, 
may be counted as comorbidities in the analysis, which would potentially underestimate the 
incremental costs of breast cancer. Fourth, the authors could not account for women in the 
survivorship phase of cancer care that may not be identified by the algorithm. Finally, the 
study did not control for insurance type, which may produce an uncertain bias in the results.
Conclusions
Despite these limitations, this study provides the first estimates of the direct medical care 
costs attributable to breast cancer for privately insured younger women. The results suggest 
that, in addition to the mortality impact,33 the medical care cost of breast cancer among 
younger women with breast cancer is high. The results also highlight the importance of 
health insurance coverage for younger women to avoid potential financial hardship.
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Table 1
Summary Statistics for Younger Women With or Without Breast Cancer Aged 18–44 Years, 2006
Variable
Women
with breast
cancer
Women without
breast cancer
(before matching)
Women without
breast cancer
(after matching)
p-value for
differences
(BC versus
matched controls)
Observations (n) 9,912 3,503,113 9,912
Costs ($; M [SE])a
  Annualized total costs 27,833 (445) 2,889 (4) 4,831 (165) < 0.01
  Annualized outpatient costs 25,516 (426) 2,212 (3) 3,798 (154) < 0.01
  Annualized inpatient costs 96 (11) 31 (0) 43 (5) < 0.01
  Annualized prescription drug costs 2,221 (66) 645 (1) 989 (29) < 0.01
Age (years) 0.48
  18–23 0.5 18.7 0.5
  24–28 5.2 14.6 5.0
  29–33 11.6 17.0 11.5
  34–38 21.5 20.4 20.6
  39–44 61.2 29.3 62.4
Employment 0.19
  Employed, full-time 71.0 67.7 72.2
  Employed, part-time 1.5 1.8 1.5
Charlson Indexb 0.85
  Charlson score of zero 88.8 92.1 88.9
  Charlson score of one 9.5 7.0 9.6
  Charlson score greater than one 1.6 0.9 1.5
Comorbidities in 2006
  Ovarian cancer 0.6 0.1 0.7 0.71
  Colorectal cancer 0.3 0.03 0.3 0.69
  Lung cancer 0.8 0.02 0.8 0.65
  Cervical cancer 0.4 0.3 0.4 0.82
  Skin cancer 1.6 0.4 1.6 0.80
  Leukemia and lymphoma 0.7 0.1 0.6 0.87
  Hypertension 8.1 5.2 8.3 0.57
  Dyslipidemia 8.8 5.5 9.3 0.58
  Pneumonia 1.2 0.6 1.4 0.55
  Asthma 2.8 2.9 2.8 0.72
  Depression 5.3 3.9 5.4 0.93
  Back problems 15.6 11.1 16.1 0.11
  Skin disorders 20.3 13.7 21.1 0.75
  Injuries 22.9 14.1 23.4 0.06
  Pregnancy 11.8 10.5 12.4 0.85
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Variable
Women
with breast
cancer
Women without
breast cancer
(before matching)
Women without
breast cancer
(after matching)
p-value for
differences
(BC versus
matched controls)
  Arthritis 13.6 8.3 14.2 0.12
  Mental health/substance abuse 12.2 9.8 12.3 0.65
Note: Values are percentages unless otherwise noted. Summary statistics are presented for younger women with breast cancer and propensity 
score–matched comparison sample. Boldface indicates a statistically significant difference from the breast cancer sample (p< 0.05).
State indicator variables were included in the match; none were significantly different than the breast cancer sample at the 5% level.
aAll costs are per capita and were adjusted to 2012 U.S. dollars.
b
This Charlson Index excludes cancers.
BC, breast cancer.
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Table 2
Summary Statistics for Younger Women With or Without Breast Cancer Aged 18–44 Years, Active Treatment 
Subsample, 2006
Variable
Women with
breast cancer
(active treatment)
Women with
breast cancer
(not on active
treatment)
Women without
breast cancer
(after matching
to active
treatment group)
p-value for
differences
(BC versus matched
controls)
Observations (n) 3,065 6,847 3,065
Costs ($; M [SE])a
  Annualized total costs 68,096 (1,077) 10,026 (174) 6,019 (314) <0.01
  Annualized outpatient costs 64,271 (1,029) 8,377 (163) 4,820 (286) <0.01
  Annualized inpatient costs 140 (18) 77 (13) 39 (8) <0.01
  Annualized prescription drug costs 3,685 (196) 1,573 (37) 1,161 (69) <0.01
Age (years) 0.83
  18–23 0.2 0.7 0.2
  24–28 1.3 6.9 1.2
  29–33 6.4 13.9 6.6
  34–38 22.3 21.2 21.2
  39–44 69.8 57.4 70.8
Employment 0.73
  Employed, full-time 69.6 71.7 70.2
  Employed, part-time 1.7 1.5 1.4
Charlson Indexb 0.85
  Charlson score of zero 86.3 90.0 86.2
  Charlson score of one 11.6 8.6 11.9
  Charlson score greater than one 2.1 1.4 1.9
Comorbidities in 2006
  Ovarian cancer 1.0 0.5 0.8 0.37
  Colorectal cancer 0.7 0.1 0.7 0.94
  Lung cancer 2.1 0.3 2.0 0.75
  Cervical cancer 0.6 0.3 0.5 0.76
  Skin cancer 2.7 1.2 2.6 0.81
  Leukemia and lymphoma 1.6 0.4 1.5 0.80
  Hypertension 10.4 7.1 10.6 0.87
  Dyslipidemia 8.8 8.8 9.6 0.31
  Pneumonia 2.1 0.9 2.5 0.34
  Asthma 2.6 2.9 2.4 0.54
  Depression 6.0 4.9 6.8 0.25
  Back problems 17.0 15.0 17.3 0.74
  Skin disorders 22.5 19.3 23.3 0.48
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Variable
Women with
breast cancer
(active treatment)
Women with
breast cancer
(not on active
treatment)
Women without
breast cancer
(after matching
to active
treatment group)
p-value for
differences
(BC versus matched
controls)
  Injuries 31.7 19.0 32.5 0.52
  Pregnancy 3.6 15.5 3.5 0.90
  Arthritis 15.9 12.5 16.9 0.33
  Mental health/substance abuse 15.1 11.0 15.8 0.41
Note: Values are percentages unless otherwise noted. Summary statistics are presented for younger women with breast cancer and propensity 
score–matched comparison sample.
Boldface indicates a statistically significant difference from the breast cancer sample (p < 0.05).
State indicator variables were included in the match; none were significantly different than the breast cancer sample at the 5% level.
aAll costs are per capita and were adjusted to 2012 U.S. dollars.
b
This Charlson Index excludes cancers.
BC, breast cancer
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Table 3
Annual Direct Medical Costs Attributable to Breast Cancer in Younger Women by Type of Service
Annualized medical
care costs per
woman ($2012)
Annualized medical
care costs per
woman in active
treatment ($2012)
Type of
service Estimate (SE) Estimate (SE)
Total costs 19,435 (415) 52,542 (977)
Outpatient 18,344 (396) 50,291 (932)
Inpatient 43 (10) 80 (17)
Prescription 1,048 (64) 2,170 (184)
Note: Total costs and outpatient costs used a generalized linear model, whereas inpatient and prescription drug costs were estimated using a two-
part model. SEs were derived using the delta method.
Boldface indicates statistical significance at the 1% level.
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